Nexstim to Present at Redeye Medtech & Diagnostics Seminar
Press release, Helsinki, September 23, 2021at 3 PM(EEST)
Nexstim to Present at Redeye Medtech & Diagnostics Seminar
Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company”) CEO Mikko Karvinen will be participating Redeye’s Medtech and Diagnostics Seminar on Tuesday September 28, 2021. Nexstim’s presentation is scheduled to start at 12:50 pm (CEST) and will include an overview of the Company as an investment.
The event will be streamed live on the Redeye website starting at 9:00 am (CEST) and a recording will be available after the event. More information on the event is available through this link >>
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Stock Exchange Release Dovre Guidance For Year 202418.4.2024 16:00:00 CEST | Press release
Dovre Group Plc Stock Exchange Release April 18, 2024, at 5.00 pm DOVRE GROUP PLC OUTLOOK FOR YEAR 2024 In 2024 our revenue is expected to be in the range of 185 - 210 MEUR and the Operating Profit (EBIT) is expected to be in the range of 2 - 4 MEUR. The lower than 2023 EBIT is due to a significant one-time write-down (approx. 6 million euros) of a single renewable project in Q1. The project was technically successful but exceeded the cost budget considerably. Corrective actions have been taken and Suvic expects the remainder of the 2024 to clearly exceed the comparison period of 2023 in both revenue and EBIT. Dovre`s Project personnel and Consulting business areas are expected to decline in both revenue and EBIT compared to 2023 due to the completion of a major project in Canada and somewhat slower activity in the Norwegian public sector. For further information: Dovre Group Plc Arve Jensen CEO Tel. +47 90 60 78 11 arve.jensen@dovregroup.com Hans Sten CFO hans.sten@dovregroup.com tel.
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN TERRANET AB18.4.2024 15:45:00 CEST | Press release
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in Terranet AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall prevail. The shareholders of Terranet AB, registration number 556707-2128, (the "Company") are hereby invited to the annual general meeting on 21 May 2024 at 11.00 a.m. at Eversheds Sutherland Advokatbyrå's premises at Sveavägen 20, 3 tr, in Stockholm. Registration starts at 10.45 am. RIGHT TO PARTICIPATE AND REGISTRATION Shareholders who wish to attend the general meeting shall: be entered in the share register maintained by Euroclear Sweden AB on 13 May 2024, and; notify the Company of their attendance at the general meeting no later than 15 May 2024 by e-mail to pal.eriksson@terranet.se or by letter to Terranet AB, Mobilvägen 10, 223 62 Lund, Sweden, marking the envelope with "Annual General Meeting 2024". In the notification, the s
KALLELSE TILL ÅRSSTÄMMA I TERRANET AB18.4.2024 15:45:00 CEST | Pressemelding
Aktieägarna i Terranet AB, org.nr 556707–2128, (”Bolaget”) kallas härmed till årsstämma den 21 maj 2024 kl. 11.00 i Eversheds Sutherland Advokatbyrås lokaler på Sveavägen 20, 3 tr, i Stockholm. Inregistrering inleds från klockan kl. 10.45. Rätt att delta och anmälan Aktieägare som önskar delta på bolagsstämman ska dels vara införd i den av Euroclear Sweden AB förda aktieboken den 13 maj 2024, dels senast den 15 maj 2024 anmäla sig för deltagande på stämman hos Bolaget via e-post till pal.eriksson@terranet.se eller per post till Terranet AB, Mobilvägen 10, 223 62 Lund, märk kuvertet med ”Årsstämma 2024”. Vid anmälan ska aktieägaren uppge namn, person- eller organisationsnummer, adress, och telefonnummer samt, i förekommande fall, uppgift om biträde (högst 2). FÖRVALTARREGISTRERADE AKTIER Aktieägare som har låtit förvaltarregistrera sina aktier måste låta registrera sina aktier i eget namn för att ha rätt att delta vid årsstämman. Sådan registrering kan vara tillfällig (s.k. rösträttsreg
Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:0018.4.2024 15:39:45 CEST | Press release
Orphazyme A/S har afholdt ordinær generalforsamling den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende dagsorden: Bestyrelsens beretning om selskabets virksomhed i det forløbne regnskabsårFremlæggelse og godkendelse af årsrapport Anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapportBeslutning om meddelelse af decharge til bestyrelsen og direktionenPræsentation af vederlagsrapportenGodkendelse af vederlag til bestyrelsen for indeværende regnskabsårValg af medlemmer til bestyrelsenValg af revisorBemyndigelse til at erhverve egne aktierEventuelle forslag fra bestyrelse eller aktionærer Der er følgende indkomne forslag fra bestyrelsen: Præcisering af selskabets virkeForlængelse af bemyndigelsen til at forhøje aktiekapitalen med fortegningsretEventuelt Bestyrelsen havde i henhold til selskabets vedtægter pkt. 4.8 udpeget Jakob Have som dirigent for den ordinære generalforsamling. Dirigenten konstaterede,
Pharming Group announces the placement of €100 million convertible bonds due 202918.4.2024 15:04:30 CEST | Press release
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the "Shares"). The offer was fully subscribed. The New Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, Canada, Japan and South Africa. The New Bonds will have a principal amount of €100,000 each. The New Bonds will be issued at par and will carry a coupon of 4.50% per annum payable semi-annually in arrear in equal instalments on 25th April and 25th October of each y